Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated rabies vaccine is a biologic product containing killed (inactivated) whole rabies virus. It is used for active immunization against the rabies virus, both as pre-exposure prophylaxis for individuals at high risk and as post-exposure prophylaxis following potential exposure to the virus. The mechanism of action involves stimulating the immune system to produce neutralizing antibodies against the viral glycoprotein, thereby preventing infection if administered before or soon after exposure. The most common formulations are produced using either human diploid cells (HDCV) or purified chick embryo cells (PCECV), with inactivation typically achieved by beta-propiolactone treatment[1][3][4][5]. The primary indication is prevention of human rabies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated rabies vaccine.